Results 21 to 30 of about 13,651 (209)

Flecainide Toxicity Secondary to Accidental Overdose: A Pediatric Case Report of Two Brothers

Case Reports in Critical Care, 2021
Flecainide is a class 1C antiarrhythmic with a narrow therapeutic window and thereby a high-risk medication for causing acute toxicity. Dysrhythmias secondary to flecainide ingestion are often refractory to antiarrhythmics and cardioversion, and patients
Sarah E. Gardner Yelton, James B. Leonard, Caridad M. de la Uz, Rajeev S. Wadia, Sean S. Barnes   +4 more
doaj   +1 more source

Flecainide in clinical practice

Cardiology Journal, 2023
Flecainide, similar to encainide and propafenone, is IC class antiarrhythmic, inhibiting Nav1.5 sodium channels in heart muscle cells and modulates cardiac conduction. Despite its over 40-year presence in clinical practice, strong evidence and well-known
Mikołaj Basza, Cezary Maciejewski, Wojciech Bojanowicz, Paweł Balsam, Marcin Grabowski, Przemysław Mitkowski, Maciej Kempa, Oskar Kowalski, Zbigniew Kalarus, Miłosz Jaguszewski, Andrzej Lubiński, Ludmiła Daniłowicz-Szymanowicz, Łukasz Szumowski, Maciej Sterliński, Łukasz Kołtowski   +14 more
doaj   +1 more source

Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor [PDF]

, 2016
Background and Purpose Flecainide is a use-dependent blocker of cardiac Na+ channels. Mechanistic analysis of this block showed that the cationic form of flecainide enters the cytosolic vestibule of the open Na+ channel.
Alvarez-Laviada, Anita, Bagley, Mark C, Bannister, Mark L, Coleman, Sharon, du Plessis, Christo L, George, Christopher H, MacLeod, Kenneth T, Mason, Sammy A, Moran, Abbygail T, Neill-Hall, David, Osman, Hasnah, Thomas, N Lowri, Williams, Alan J   +12 more
core   +1 more source

Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12 months: a retrospective study

Therapeutic Advances in Cardiovascular Disease, 2020
Introduction: Current atrial fibrillation (AF) guidelines recommend flecainide as a first-line rhythm control option in patients without structural heart disease. While there is proven efficacy in clinical trials and guideline support, it is hypothesized
Mikayla Muzzey, Katie B. Tellor, Karthik Ramaswamy, Martin Schwarze, Anastasia L. Armbruster   +4 more
doaj   +1 more source

Flecainide-Associated Cardiogenic Shock in a Patient with Atrial Fibrillation

Case Reports in Cardiology, 2019
Flecainide is a frequently used antiarrhythmic drug, recommended by current guidelines as a first-line treatment option for restoring and maintaining sinus rhythm in patients with atrial fibrillation and no significant structural heart disease.
Erind Gjermeni, Andreas Bollmann, Gerhard Hindricks, Andreas Müssigbrodt   +3 more
doaj   +1 more source

Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients

Frontiers in Pharmacology, 2020
The prolongation of the QT interval represents the main feature of the long QT syndrome (LQTS), a life-threatening genetic disease. The heterozygous SCN5A V411M mutation of the human sodium channel leads to a LQTS type 3 with severe proarrhythmic effects
Jordi Cano, Esther Zorio, Esther Zorio, Andrea Mazzanti, Andrea Mazzanti, Miguel Ángel Arnau, Beatriz Trenor, Silvia G. Priori, Silvia G. Priori, Javier Saiz, Lucia Romero   +10 more
doaj   +1 more source

Flecainide Improve Sepsis Induced Acute Lung Injury by Controlling Inflammatory Response [PDF]

Korean Journal of Critical Care Medicine, 2016
Background: Flecainide is an antiarrhythmic agent that is used primarily in the treatment of cardiac arrhythmias. Some evidences also suggest that flecainide can participate in alveolar fluid clearance and inflammatory responses.
Jia Song, Young joong Suh, Hyun jung Lee, Eun a Jang, Hong-beom Bae, Sang-Hyun Kwak   +5 more
doaj   +1 more source

Common Structural Pattern for Flecainide Binding in Atrial-Selective K_v1.5 and Na_v1.5 Channels: A Computational Approach

Pharmaceutics, 2022
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Its treatment includes antiarrhythmic drugs (AADs) to modulate the function of cardiac ion channels.
Yuliet Mazola, José C. E. Márquez Montesinos, David Ramírez, Leandro Zúñiga, Niels Decher, Ursula Ravens, Vladimir Yarov-Yarovoy, Wendy González   +7 more
doaj   +1 more source

Managing atrial fibrillation in the global community: The European perspective. [PDF]

, 2013
Atrial fibrillation is a common, global problem, with great personal, economic and social burdens. As populations age it increases in prevalence and becomes another condition that requires careful chronic management to ensure its effects are minimised ...
Camm, AJ, Kaba, RA, Sharma, R, Williams, TM   +3 more
core   +1 more source

Brugada pattern masquerading as ST-segment elevation myocardial infarction in flecainide toxicity

Indian Heart Journal, 2012
Flecainide (a class 1c antiarrhythmic) produces a dose-dependent decrease in intracardiac conduction. Its well known common electrocardiographic effects are prolongation of PR and QT intervals and the QRS complex duration.
Lovely Chhabra, David H. Spodick
doaj   +1 more source